Oragenics Inc. (OGEN)
0.28
-0.00 (-1.75%)
At close: Mar 13, 2025, 1:03 PM
-1.75% (1D)
| Bid | 0.28 |
| Market Cap | 3.57M |
| Revenue (ttm) | -72.5K |
| Net Income (ttm) | -38.45M |
| EPS (ttm) | -6.97 |
| PE Ratio (ttm) | -0.04 |
| Forward PE | -0.03 |
| Analyst | n/a |
| Ask | 0.29 |
| Volume | 141,049 |
| Avg. Volume (20D) | 5,627,037 |
| Open | 0.29 |
| Previous Close | 0.28 |
| Day's Range | 0.28 - 0.29 |
| 52-Week Range | 0.25 - 3.43 |
| Beta | 0.85 |
About OGEN
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 25, 2004
Employees 5
Stock Exchange AMEX
Ticker Symbol OGEN
Website https://www.oragenics.com
5 months ago
+6.39%
Oragenics shares are trading higher after the comp...
Unlock content with
Pro Subscription
6 months ago
-46.2%
Oragenics shares are trading lower after the company announced $4.45 million public offering of 8,106,584 shares at $0.55 per share.
